Sa1041 Triple Therapy Under Real Life Conditions: Telaprevir (TVR) and Boceprevir (BOC) in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) in Treatment Experienced Patients Infected With Chronic Hepatitis C, Genotype 1. the PAN Study

A S L D A b st ra ct s (± SD) of 8.4 (±8.9) weeks from the time of viral breakthrough. Resistance patterns were detected in 6 of 8 (75%) patients and all patients had cross-resistance to boceprevir. All 4 patients with higher-level resistance patterns were genotype 1a. Both patients who tested sensitive were genotype 1b. Conclusion: Similar to findings in clinical trials, viral breakthrough with DAA for treatment of chronic HCV infection is associated with genotype 1a, advanced liver fibrosis, and prior null treatment response. Comparable patterns of resistance were also seen in clinical practice. In our study, however, a significant proportion of patients experienced viral breakthrough after completion of the DAA portion of triple therapy. More frequent virologic assessments during the PR treatment phase may be useful in a subset of "higher-risk" patients to expedite compliance with stopping rules and decrease unnecessary treatment burden. Treatment Response of Patients with Viral Breakthrough